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ABSTR ACT: In spite of the global reputation of ethanol as the psychopharmacologically active ingredient of alcoholic drinks, the neurobiological basis 
of the central effects of ethanol still presents some dark sides due to a number of unanswered questions related to both its precise mechanism of action and 
its metabolism. Accordingly, ethanol represents the interesting example of a compound whose actions cannot be explained as simply due to the involvement 
of a single receptor/neurotransmitter, a scenario further complicated by the robust evidence that two main metabolites, acetaldehyde and salsolinol, exert 
many effects similar to those of their parent compound. The present review recapitulates, in a perspective manner, the major and most recent advances that 
in the last decades boosted a significant growth in the understanding on the role of ethanol metabolism, in particular, in the neurobiological basis of its 
central effects.
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Introduction
Ethanol is the main psychopharmacologically active ingre-
dient of alcoholic drinks and, accordingly, is recognized as 
the compound potentially responsible for alcohol use dis-
orders (AUDs), as defined by the Diagnostic and Statistical 
Manual of Mental Disorders (fifth edition),1 as well as for 
a number of alcohol-related chronic diseases that heav-
ily affect individuals and society. In Europe, AUDs and 
AUD-related pathologies (mostly liver, cardiological, and 
neurological disorders) affect over 4 million people, costing 
roughly 740 million euros in terms of direct and indirect 
costs,2 whereas in the USA, these numbers roughly approxi-
mate to 16.3 million people3 and 223.5 billion USD.4–6 
Consequently, understanding the neurobiological basis of 
AUDs still represents a main challenge for the scientific 
community devoted to disclose the mechanisms at the basis 
of the ability of this simple compound to alter behavior. 
The disclosure of its mechanism(s) of action could allow the 
progress toward the availability of new medications useful 
to prevent and treat AUDs.
Interestingly, although the molecular target(s) of etha-
nol have not yet been precisely determined, a large body of 
literature refers to its central effects as primarily due to an 
action onto GABAA receptors, whereby the acute action of 
ethanol results in a facilitation of inhibitory conductance 
mediated by this receptor channel.7 Moreover, it also acts 
onto N-Methyl-D-Aspartate (NMDA) glutamate receptors, 
whereby ethanol acutely inhibits excitatory currents mediated 
by NMDA–Ca2+ channels.8 In addition to these mechanisms, 
the indirect involvement of the opioid,9,10 adenosine,11 and 
mesolimbic dopaminergic12 systems has become acquainted 
with some of the neurochemical,13–15 behavioral,9 and motiva-
tional16 acute effects of ethanol.
This review focuses on the role of peripheral and central 
metabolism of ethanol and on the role of its main biologically 
active metabolites, acetaldehyde and salsolinol, in the acute 
actions of their parent compound. A particular emphasis 
will be placed on the effects that acetaldehyde and salsolinol 
exert on the mesolimbic dopaminergic system as they appear 
rich in critical implications in the motivational properties 
of ethanol itself and represent a still promising pathway of 
investigation toward the understanding of the neurobiologi-
cal basis of AUDs and the discovery of suitable targets for its 
pharmacotherapy.
Peripheral Metabolism of Ethanol
The metabolic disposal of ethanol in the body, which yields 
acetaldehyde and acetate, may take place through different oxi-
dative pathways depending on the differential expression of the 
involved enzymes in different organs. The main metabolic path-
way responsible for ethanol metabolism is represented by type 
II alcohol dehydrogenase (ADH), the other isoforms of ADH 
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(I, III, and IV) being mostly active on alcoholic substrates with 
a different structure and/or longer aliphatic chains.17 ADH 
is a nicotinamide adenine dinucleotide-dependent cytosolic 
enzyme that may be distinguished in different isoforms as a 
function of their subunit composition17 and whose efficiencies 
may differ significantly. Accordingly, although after oral etha-
nol ingestion ADH represents the first significant exposure of 
ethanol to the enzymes responsible for its metabolism, the low 
efficiency of gastric enzymes and the high expression of ADH 
in the liver make hepatic metabolism the main oxidative path-
way responsible for its disposal. Some exceptions, however, do 
exist. In fact, gastric ADH in most cases is a poorly efficient 
isoform (ie, works under a first-order kinetic until the sub-
strate reaches a saturating concentration at which the enzyme 
switches to a zero-order kinetic) unless factors such as gender 
(females express more efficient gastric ADH isoforms than 
males) and fasting (stomach emptiness elicits enzymatic induc-
tion) increase their metabolic rate.17 Moreover, genetic differ-
ences are critical in understanding the consequences of ethanol 
metabolism on its effects. Thus, type 2 ADH (ADH2*2) is a 
highly efficient variant of ADH abundantly expressed in indi-
viduals of the Asian population that accounts for their high 
susceptibility to the aversive effects of acetaldehyde. In addi-
tion, in these subjects, an increase in acetaldehyde in plasma 
following ethanol ingestion is sustained and prolonged by the 
simultaneous expression of a poorly efficient isoform of alde-
hyde dehydrogenase (ALDH), the enzyme responsible for the 
oxidation of acetaldehyde into acetate. Therefore, Asians are 
generally more sensitive to the toxic effects of acetaldehyde as 
a consequence of the simultaneous presence of a more efficient 
enzymatic conversion of ethanol into acetaldehyde and of a less 
efficient conversion of acetaldehyde into acetate (Fig. 1).17
However, although ethanol metabolism has been conven-
tionally viewed as carried out by liver ADH1 (class I), it has to 
be taken into account that other pathways, in particular in the 
presence of high blood ethanol levels or high drinking, may 
also play an important role in ethanol peripheral metabolism. 
Thus, besides ADH1, other components of the enzymatic 
machinery responsible for ethanol oxidation such as the 
Nicotinamide Adenine Dinucleotide Phosphate Hydrogen 
(NADPH)-dependent microsomal ethanol oxidizing18 and 
the catalase–H2O2 systems should be taken into account, 
although their contributions have yet to be fully clarified. In 
particular, in the microsomal ethanol oxidizing pathway, resi-
dent in the smooth endoplasmic reticulum and involving the 
2E1 isoform of cytochrome P450, ethanol is converted into 
acetaldehyde by the redox reaction in which O2 is reduced to 
form H2O, whereas in the catalase–H2O2 system, ethanol is 
oxidized into acetaldehyde within the peroxisomes19 by taking 
H2O2 as a co-substrate to form compound I (Fig. 2).20
Moreover, Haseba and Ohno21 reported that ADH3 
(class III) may contribute to peripheral ethanol metabolism, 
thereby diminishing the consequences of acute ethanol intoxi-
cation and eventually supporting the ADH1-mediated etha-
nol metabolic disposal.21
Peripheral Ethanol Metabolism: Beyond ADH
Inhibition of (peripheral) ADH has been described to decrease 
brain acetaldehyde concentration, and this is contrary to what 
would be predicted since, not being disposed in the periph-
ery, ethanol would be expected to reach the brain in greater 
amounts. As a consequence, also acetaldehyde concentrations, 
following ethanol’s cerebral metabolism, should be expected 
to be increased. In this regard, Bradford et al in 1993 hypoth-
esized that the contribution of ADH to ethanol metabolism 
may have been overestimated.22,23 In fact, administration 
to rats of 4-methylpyrazole (4-MP),24 a potent inhibitor of 
ADH, resulted in a very low rate of ethanol elimination, sug-
gesting that ADH could not be the main or the only pathway 
responsible.25 This conclusion, however, was partly in contrast 
with the clinical observation that 4-MP inhibits the oxidation 
of ethanol in humans.26
Remarkably, in this regard, 4-MP has also been shown to 
inhibit Acyl-CoA synthase,22,23 an enzyme essential to initiate 
the process of fatty acid oxidation (Fig. 3). Thus, by blocking 
Figure 1. schematic representation of the main, peripheral and central, 
metabolic pathways by which ethanol is oxidized into acetaldehyde and 
acetate.
Abbreviations: acD, acetaldehyde; EtoH, ethanol; aDH, alcohol 
dehydrogenase; alDH, aldehyde dehydrogenase; cYp2E1, cytochrome 
p450, isoform 2E1.
Figure 2. schematic representation of the catalase–H2o2 metabolic 
pathway by which ethanol is oxidized into acetaldehyde.
Abbreviations: acD, acetaldehyde; EtoH, ethanol.
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fatty acid oxidation, the generation of H2O2 in the peroxisomes 
is prevented and liver catalase is indirectly inhibited.22,23,27
In agreement with this possibility, Handler et al28 sug-
gested that liver catalase plays a critical role in the conversion 
of ethanol into acetaldehyde. This observation indicates that 
hepatic ethanol metabolism may be mediated predominantly 
by catalase–H2O222,23,27 and also suggests that simultaneous 
inhibition of peripheral ADH and peripheral catalase–H2O2 
could result in the almost quantitative prevention of ethanol 
metabolism.
Interestingly, the possibility that peripherally produced 
acetaldehyde may have a significant role in the central effects 
of ethanol has long been questioned also on the basis of the 
observation that it may poorly cross the blood–brain barrier 
(BBB).29–31 However, this issue has been settled by the obser-
vation that ALDH highly expressed in the endothelial cells 
of the BBB may allow the distribution of acetaldehyde into 
the brain only in its presence at saturating concentrations 
(transforming the BBB into the so-called enzymatic barrier for 
acetaldehyde). In addition, it should be kept in mind that the 
experiments with the use of peripheral inhibitors of ethanol 
metabolism suffer of the following intrinsic limitations: first, 
the blockade of ADH or interference with liver catalase–H2O2 
system may determine a reduction in blood ethanol-derived 
acetaldehyde,32 therefore, not available to eventually exert its 
peripheral and/or central effects, and second, the blockade of 
ADH or interference with liver catalase–H2O2 system may 
also (and simultaneously) determine an increase in ethanol 
availability for its central actions.
Central Metabolism of Ethanol
Brain catalase. In the central nervous system also, 
the enzyme catalase takes H2O2 as a co-substrate to form 
compound I (Fig. 2),20 which is the main metabolic intermedi-
ate for the metabolism of ethanol.33,34 The distribution of brain 
catalase expression has been investigated by the immunohisto-
chemical approach disclosing that catalase is localized mainly 
in the body of catecholaminergic neurons of the midbrain and 
of the brain stem.35,36 Brain catalase staining appears weaker 
than that in the liver and its distribution appears overall lim-
ited as compared to ALDH staining which, in contrast, is 
widely expressed in a number of brain structures.33,37 How-
ever, acetaldehyde is still generated locally in pharmacologi-
cally significant amounts.33 Accordingly, when brain catalase 
activity is impaired either pharmacologically38,39 and geneti-
cally,40 acetaldehyde production from brain homogenates 
incubated with ethanol is significantly reduced. This confirms 
that compound  I (Fig. 2) is the intermediate which is also 
critically implicated in the central production of acetaldehyde; 
hence, for this reason, it is also realistic to admit that both the 
catalase–H2O2 system and the cellular bioavailability of H2O2 
(Fig. 3) may determine the rate of acetaldehyde formation.41–43
Detection of acetaldehyde. Over the years, a number 
of experimental issues (methodological and related to limits 
of detection) have made difficult to gain the present critical 
understanding on the neurophysiological and neurochemical 
properties of acetaldehyde and on its role in the central effects 
of ethanol. The first of these critical issues was related to the 
quantitative measurements of acetaldehyde in the blood and, 
especially, in the brain. Jamal et al44 provided a procedure 
to detect acetaldehyde in living animals by in vivo brain 
microdialysis.44 However, the detection of acetaldehyde was 
limited to the condition in which its metabolism was inhib-
ited by the ALDH inhibitor, cyanamide. The second critical 
issue was represented by acetaldehyde’s redox transforma-
tions. In fact, besides its prompt liver and brain oxidation by 
ALDH2 into acetate, acetaldehyde can also be removed as 
a consequence of its reduction into ethanol by liver ADH.33 
Moreover, another critical issue, representing a limiting 
factor for the detection of acetaldehyde in the periphery and 
in the brain, is related to the fact that this chemical retains a 
very short (minutes) plasmatic elimination half-life45–47 due, 
at least partly, to its high electrophilic reactivity and, there-
fore, to its ability to bind to nucleophilic structures and give 
condensation products or adducts.48–52
Role of Acetaldehyde in the Motivational Effects 
of Ethanol and Involvement of the Dopaminergic 
System
Converging evidence attributes to either peripheral or central 
metabolism of ethanol into acetaldehyde a critical role in 
many of ethanol’s central effects, including the ability to affect 
motivation.50,53 Notably, while the peripheral metabolism of 
ethanol into acetaldehyde may result in central effects depend-
ing on the conditional capability of acetaldehyde to cross the 
BBB,37 its central metabolism mostly depends on the activity 
of catalase–H2O2 system.38
Both ethanol-derived acetaldehyde and acetaldehyde on 
its own have been shown to involve the mesolimbic dopa-
minergic system in their central effects. Evidence, in this 
regard, originated from the observation that, similarly to 
ethanol,54 orally administered acetaldehyde can also stimulate 
Figure 3. schematic representation of the mechanism by which 4-methyl 
pyrazole may interfere with catalase–H2o2-mediated ethanol metabolism. 
4-methyl pyrazole may inhibit the acylation of fatty acids by inhibiting 
acyl-coa synthase and reducing H2o2 availability for catalase–H2o2-
mediated ethanol metabolism.
Abbreviations: 4-mp, 4-methyl pyrazole; acD, acetaldehyde; 
EtoH, ethanol.
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spontaneous firing of dopaminergic neurons in the ventral 
tegmental area (VTA),55 a finding also in agreement with 
the observation that acetaldehyde stimulates dopamine trans-
mission in the nucleus accumbens as determined by in vivo 
brain microdialysis.56,57 Furthermore, indirect evidence of the 
involvement of the mesolimbic dopaminergic system in the 
effects of either acetaldehyde or ethanol-derived acetaldehyde 
(as demonstrated by the combined administration of ethanol 
and 4-MP or d-penicillamine, a compound able to sequester 
acetaldehyde) arose from the studies reporting their ability to 
elicit the activation of the extracellular signal-regulated kinase 
pathway58,59 in the nucleus accumbens.60
Until now, at least the following four distinct pieces of 
evidence support the role of ethanol-derived acetaldehyde in 
these effects of ethanol:50,53
(i) the demonstration that the effects of peripherally admin-
istered ethanol may be prevented by drugs able to contrast 
peripheral ethanol metabolism (ADH inhibitors);32,55,56,60
(ii) the demonstration of the ability to prevent the effects of 
systemic administration of ethanol by drugs that inhibit 
and/or interfere with catalase–H2O2 system;41–43,61
(iii) the demonstration that a reduction in acetaldehyde avail-
ability by sequestering drugs could produce a reduction 
in the effects of ethanol either after its peripheral admin-
istration or after its central administration;32,61–67
(iv) the demonstration that acetaldehyde exerts effects simi-
lar to those of ethanol after its peripheral32,60,65,68–71 or 
local, intracerebral,72–75 administration.
Thus, based on these premises, a number of studies on 
the role of acetaldehyde in the motivational effects of ethanol 
support the suggestion of a critical role played by acetalde-
hyde, both on its own and as ethanol-derived. These studies 
were mainly performed, in rats, after ethanol or acetaldehyde 
non-contingent (intragastric) administration by conditioned 
place preference (CPP)32,56,71 and after oral operant ethanol 
and/or acetaldehyde self-administration43,61,65,66,68,76 experi-
ments. Remarkably, in CPP experiments, the doses of acetal-
dehyde and ethanol were of 20 mg/kg and 1 g/kg, respectively, 
indicating that acetaldehyde could be 50-fold more potent 
than ethanol. Similarly, acetaldehyde was reported to 
determine CPP after intraperitoneal69 and intragastric 
administrations32,56 as well as after ICV infusion.70 Remark-
ably, the inhibition of ADH and the reduction of acetaldehyde 
bioavailability were reported to similarly reduce the acquisi-
tion of ethanol-induced CPP.32
Other studies further clarified the role of ethanol-derived 
acetaldehyde in the motivational effects of ethanol, as deter-
mined by CPP experiments in rats of two lines selectively 
bred for their high (UChB) or low (UChA) voluntary etha-
nol intake.77 In these experiments, in ethanol-naive animals 
of both lines, ethanol was reported to elicit a conditioned 
place aversion that was reverted to CPP in UChB rats by a 
period of voluntary, free-choice intake of ethanol, whereas in 
UChA rats, in order to facilitate the development of ethanol-
elicited CPP, both a period of forced ethanol drinking and the 
administration of 4-MP were necessary. This suggested that 
in UChA rats, the possibility to acquire ethanol-elicited CPP 
was dependent upon prior ethanol exposure and upon reduc-
tion in high blood ethanol-derived acetaldehyde.77
In operant experiments, on the other hand, acetaldehyde 
was reported to be self-administered orally65,78 or intracere-
broventricularly by ethanol-naive rats72–74 into the VTA by 
alcohol-preferring (P) rats,79 as well as intravenously.75 In par-
ticular, our recent studies have pharmacologically character-
ized acetaldehyde self-administration by showing that it could 
be prevented by the blockade of μ opioid receptors, with both 
naltrexone and naloxonazine,68 and by the sequestering agent 
l-cysteine.80
Acetaldehyde in the Maintenance Phase and the First 
Hit Hypothesis
A more recent and refined research on the role played by acet-
aldehyde in the ability of ethanol to elicit and maintain its 
self-administration disclosed that in ethanol-naive rats, acet-
aldehyde plays a critical role as first hit in the acquisition of 
self-administration.61,81 In fact, the initial development of 
reinforcement (first hit) during the acquisition of voluntary 
ethanol intake and of the operant behavior could be prevented 
by reducing the generation of brain acetaldehyde,40,61,82–84 
by increasing its degradation,85 or also by sequestering it 
with d-penicillamine or l-cysteine.61,64,66,67,76 This research, 
focused on the role of acetaldehyde in the initiation (eg, early 
acquisition) phase, strikingly contrasts with the studies aimed 
at characterizing the role of acetaldehyde in other late/chronic 
phases, such as long-term maintenance, but not reinstate-
ment upon deprivation, which can be considered as a short-
term reacquisition phase of the self-administration behavior 
(Fig. 4, path R).
Figure 4. schematic representation of the behavioral consequences of 
the pharmacological manipulation of the catalase–H2o2-mediated ethanol 
metabolism (r) or of acetaldehyde bioavailability (r). path l indicates the 
effects of (non-metabolized) ethanol; path r indicates the effects of both 
interference (4-mp or 3-at) with catalase–H2o2-mediated acetaldehyde 
production and reduction (d-pEn) of acD bioavailability.
Abbreviations: 4-mp, 4-methyl pyrazole; 3-at, 3-amino-1,2,4-
aminotriazole; acD, acetaldehyde; d-pEn, d-penicillamine; EtoH, ethanol.
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Accordingly, in the maintenance phase, when a 
stable chronic ethanol intake, eg, operant ethanol self-
administration, has already been reached, the reduction in 
acetaldehyde generation,61,86–88 the increase in acetalde-
hyde degradation,85 and the administration of acetaldehyde-
sequestering agents61 were not able to decrease the persistent 
ethanol intake. Thus, chronic operant ethanol intake (mainte-
nance upon operant behavior) seems to become independent 
from the critical presence of acetaldehyde (Fig. 4, path R) as in 
the initial reinforcing mechanism(s) responsible for the first hit 
(Fig. 4, path L).61,81,87 Notably, maintenance is characterized 
by on-going oral ethanol self-administration in which rats 
have reached a stable baseline rate of ethanol intake. During 
this phase, however, acetaldehyde might also, although indi-
rectly, contribute by a combined mechanism: on one hand, its 
lack might result in further ethanol seeking and taking61 and, 
on the other hand, the inhibition of catalase-mediated ethanol 
metabolism by 3-amino-1,2,4-aminotriazole (3-AT) might 
release the action of an non-metabolized fraction of ethanol 
onto GABAA receptors, as suggested for other central effects 
of ethanol by Martì-Prats et al89,90 that might result in further 
perpetuating ethanol intake (maintenance)61 (Fig. 4, path L).
Interestingly, in this regard, recent fascinating studies 
have shown that ethanol-derived acetaldehyde or acetalde-
hyde on its own may possess opposite effects, with respect 
to ethanol, after its intraperitoneal administration91 or intra-
VTA.89,90 In particular, brain-generated acetaldehyde, after 
intra-VTA ethanol administration, may be involved in the 
stimulant effects of ethanol (ethanol-induced locomotion) via 
a μ opioid receptor-mediated mechanism89 (Fig. 4, path R), 
whereas, in contrast, the nonbiotransformed fraction of etha-
nol, acting through the GABAA receptors, might account 
for the locomotor depressant effects89,90 (Fig. 4, path L). 
Similarly, peripheral administration or accumulation of acet-
aldehyde produces anxiogenic effects and induces endocrine 
stress responses.91
Consequently, when we state that ethanol-derived acet-
aldehyde could be involved in the motivational properties of 
ethanol, we should not exclude the possibility that a non-
metabolized fraction of ethanol could act, for instance, onto 
GABAA receptors to exert these effects. It is worth noting, 
in this regard, that the administration of l-cysteine blocks 
the acquisition and also maintenance as well as reinstate-
ment of drinking and seeking behaviors and the progressive 
ratio of oral ethanol self-administration.66,76 Consistently, the 
pro-drug of l-cysteine, N-acetyl cysteine, has been reported 
to not influence the acquisition of chronic ethanol intake but 
to greatly inhibit ethanol intake when it is administered to 
animals that are consuming ethanol chronically.87 Perhaps 
the ability of l-cysteine to bind to acetaldehyde is responsible 
for just the inhibition of acquisition and the reinstatement of 
ethanol self-administration. In fact, d-penicillamine, a syn-
thetic amino acid that strongly binds acetaldehyde, inhib-
its the deprivation effect of voluntary ethanol intake67 and 
ethanol relapse-like drinking in operant self-administration 
paradigm.92 This interpretation is supported by the observa-
tion that l-cysteine (but not N-acetyl cysteine) may act by 
different mechanisms on the acquisition and maintenance of 
ethanol self-administration. In this regard, we have recently 
shown a marked increase in the expression of the cystine/
glutamate exchanger in the nucleus accumbens of ethanol 
dependent rats that, under chronic ethanol taking, reach on 
average 6–14 g/kg/day of ethanol intake.93 Such an increase in 
the cystine/glutamate exchanger has been interpreted to repre-
sent a compensatory mechanism, although not efficient under 
normal or low cystine levels, to reduce extracellular glutamate 
levels to normal. In fact, rats that consume high ethanol levels 
show marked increases in extracellular glutamate.94,95 How-
ever, the peripheral administration of l-cysteine or N-acetyl 
cysteine during maintenance could potentiate the cystine/
glutamate exchanger level, which might restore extracellular 
glutamate levels to normal.87,93
However, the idea that acetaldehyde might be respon-
sible for the first hit is in contrast with other studies reveal-
ing that a negative interference with catalase–H2O2 metabolic 
pathway has been shown to impair the maintenance and fur-
ther phases of oral ethanol self-administration43 as well as of 
voluntary ethanol intake.83 It is possible that the interference 
with catalase–H2O2 operated by a-lipoic acid (a-LA), in this 
study, could be a stronger mechanism, more capable to reduce 
central (and peripheral) acetaldehyde production. Certainly, 
the interpretation of these outcomes is still unknown and 
necessitates further investigations.
Finally, in the context of the present review, it is critical 
to at least remember that there is a possibility of the formation 
of several other metabolites of ethanol such as fatty acid ethyl 
esters96 and phosphatidylethanol.97 Moreover, the production 
of fatty acid ethyl esters could be associated with an increased 
availability of H2O2, and this might support the explana-
tion by which drugs such as a-LA and l-cysteine that are 
able to reduce H2O2 levels could decrease oral operant ethanol 
self-administration behavior by interfering with the neuroin-
flammatory process induced by ethanol or with the oxidative 
stress caused by acetaldehyde.98 In fact, a recent work shows 
that the toll-like receptor 4 is involved in the induction of 
cytokines and chemokines responsible for promoting neuro-
inflammation, brain damage, behavioral and cognitive dys-
functions, and addiction. It is important to note that selective 
inhibition of toll-like receptor 4, although in the presence of 
dose-dependent non-specific effects, such as reduced animal 
locomotor activity, saccharine intake, and lower body core 
temperature, decreased ethanol drinking in both ethanol-
dependent and non-dependent mice.99
From Ethanol to Salsolinol: is Ethanol a Pro-drug 
of Salsolinol?
As previously anticipated, acetaldehyde, whose structure 
provides this molecule a high electrophilic reactivity and, 
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consequently, a very short half-life, is not the only pharma-
cologically active metabolite of ethanol. In fact, the physi-
cal–chemical properties of acetaldehyde confer this molecule 
a high reactivity with nucleophilic compounds such as mono-
amines to produce different tetrahydroisoquinolines.48,49,52 
In particular, acetaldehyde may react with dopamine either 
spontaneously48,49,52 or enzymatically,100 although the latter 
possibility still represents an issue of controversy, to yield salsoli-
nol, 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline.
The involvement of salsolinol in alcoholism has been con-
troversial over several decades since the reported levels of salso-
linol intake and their changes after ethanol exposure were not 
consistent, possibly due to inadequate analytical procedures 
and confounding factors such as diet and genetic predisposi-
tion. Accordingly, although to the best of our knowledge no 
studies have been provided to demonstrate a direct, quantita-
tive, correlation between ethanol administration, blood etha-
nol levels, and salsolinol concentrations (in the blood and/or in 
the brain), it was reported that salsolinol is found in the brain 
following ethanol administration.44 In contrast, Lee et al101 
observed that neither ethanol self-administration nor ethanol 
administration resulted in the changes of plasma or nucleus 
accumbens salsolinol levels in men and P rats, respectively.101
All this notwithstanding, and based on the observation 
that salsolinol exerts a number of behavioral and neurochemi-
cal effects similar to those of ethanol,50,51 it was suggested 
that at least some of the effects of ethanol could be medi-
ated by salsolinol, a possibility put forward long time earlier49 
but never conclusively established.51,102 This demonstration, 
restricted to the actions of ethanol on dopamine neurons, was 
provided recently in a study conducted recording the changes 
of spontaneous firing activity of dopaminergic neurons from 
the posterior VTA in mesencephalic slices.103 In particular, 
using slices from mice administered a-methyl-p-tyrosine, an 
agent that could inhibit newly synthetized dopamine and its 
synaptic release,104 this study challenged the hypothesis that 
ethanol may be a pro-drug of salsolinol by demonstrating that 
the formation of salsolinol and, hence, the ability of ethanol 
to increase the spontaneous firing rate of dopamine neurons in 
the posterior VTA could take place under the following two 
strictly controlled sequential events: the conversion of etha-
nol into acetaldehyde and the formation of salsolinol follow-
ing condensation, of the newly-produced acetaldehyde, with 
dopamine. In particular, in the first experiment, it was con-
firmed the metabolic conversion of ethanol into acetaldehyde 
by the action of catalase–H2O2,56 and in the second experi-
ment, it was demonstrated the critical role of condensation of 
such ethanol-derived acetaldehyde with extracellular dopa-
mine to form salsolinol and to stimulate spontaneous firing of 
dopamine neurons.103 These sequential steps were controlled, 
respectively, by the use of the catalase–H2O2 inhibitor, 3-AT, 
or the H2O2 scavenger, a-LA,103 and by the use of a-methyl-
p-tyrosine. In particular, in agreement with previous studies, 
it was shown that ethanol (100  mM),56,105 acetaldehyde 
(10 nM),56 and salsolinol (10 nM)106,107 significantly increase 
the spontaneous firing rate of dopaminergic neurons in slices 
from control animals (eg, not administered with a-methyl-
p-tyrosine); however, it was also shown that only salsolinol 
(10  nM) could do so in slices from a-methyl-p-tyrosine-
administered mice.103 Furthermore, this study showed that 
the failure of ethanol (100 mM) to stimulate the spontaneous 
firing rate of dopamine neurons from a-methyl-p-tyrosine-
administered mice could be reverted by the addition of exog-
enous dopamine.103 Thus, the first experiment confirmed that, 
without its catalase–H2O2-mediated conversion into acetal-
dehyde, ethanol fails to stimulate the firing activity of dopa-
mine neurons, whereas the second experiment disclosed that 
the presence of extracellular dopamine is necessary in order 
to form salsolinol and stimulate the spontaneous firing of 
dopamine neurons. A further proof that salsolinol is indeed 
the chemical responsible of ethanol-mediated stimulation of 
the dopaminergic firing was provided by the observation that 
salsolinol could be found only in the media containing slices 
from a-methyl-p-tyrosine-administered mice in which exog-
enous dopamine was added and the stimulation of firing rate 
could be recorded.103
Effects of Salsolinol After Local or Systemic 
Administration
Long before the demonstration that, at least in vitro and at 
least for its effects on dopamine neurons in the posterior VTA, 
ethanol acts as the pro-drug of salsolinol103 and the effects of 
this compound have been studied after both its systemic and 
local (non-contingent and contingent) administration. The 
consequences of the intracerebral administration of salsolinol 
were addressed in an early study in long-sleep and short-sleep 
mice following the systemic administration of ethanol.108 
In this study, the effects of salsolinol on spontaneous activ-
ity in the open field and on ethanol-induced sleep time were 
evaluated in both lines of mice selectively bred for differen-
tial sleep time and it was found that at low doses, salsolinol 
could stimulate locomotor activity and decrease the sleep time 
of short-sleep mice, whereas at higher doses (40 μg), it could 
decrease locomotor activity and increase sleep time of both 
lines of mice,108 suggesting that at appropriate concentrations, 
the effect of salsolinol could be additive to those of ethanol.
The ability of salsolinol to exert reinforcing effects upon 
non-contingent systemic administration was reported by 
Matsuzawa et al.109 In this study, salsolinol was reported to 
dose-dependently elicit CPP both in normal rats and in rats 
subjected to stress. Furthermore, this study was the first 
to provide in vivo support to the early suggestion that the 
effects of salsolinol could be mediated by μ opioid receptors 
with the use of b-funaltrexamine.109 Notably, the reinforcing 
properties of salsolinol were demonstrated in a study in which 
salsolinol was also shown to sustain acquisition and main-
tenance of its intra-posterior VTA administration in Wistar 
rats110 in a concentration-dependent manner. Moreover, the 
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consequences of the local application of salsolinol in discrete 
brain regions (nucleus accumbens or posterior VTA) and 
the role of blockade of μ opioid receptors in these effects 
have recently also been thoroughly investigated. In particu-
lar, Hipólito, Polache, Granero and Colleagues reported in 
three different studies that the local application of salsoli-
nol in the shell and core of the nucleus accumbens differ-
entially affects dopamine transmission in these accumbal 
subregions111 and that the application of salsolinol in the 
posterior VTA, concentration dependently, stimulates loco-
motor activity and dopamine transmission in the shell of 
the nucleus accumbens.112,113 Interestingly, although these 
studies do not provide direct evidence of the relationship 
between ethanol and salsolinol, given the possibility that 
salsolinol may be metabolically generated following ethanol 
administration103 and given the similarities of the effects of 
ethanol and salsolinol,111–113 they appear highly suggestive of 
the fact that salsolinol may play a critical role in the effects 
of ethanol.51 Furthermore, although to our knowledge no 
studies have characterized fully the binding affinity of sal-
solinol for μ opioid receptors,114 the results of the studies 
by Hipólito et al111–113 strongly suggest the involvement of 
μ opioid receptors in these effects of salsolinol. An interest-
ing and robust support to this interpretation has been pro-
vided by electrophysiological studies in which dopaminergic 
neurons from posterior VTA of mesencephalic slices were 
recorded following the application of salsolinol. In this study, 
Xie et al107 demonstrated that salsolinol excites dopaminergic 
neurons by activating μ opioid receptors and inhibiting 
GABA neurons in the posterior VTA.
Salsolinol: the Issue of Stereoselectivity
More recently, Quintanilla et al115 reported the results of their 
studies on the effects of salsolinol, injected intraperitoneally 
or intracerebrally to ethanol-naive rats, bred as alcohol drink-
ers to study its motivational effects and its role on voluntary 
ethanol intake. In these experiments, salsolinol produced CPP 
and increased the locomotor activity, whether injected intra-
peritoneally or intra-posterior VTA. Furthermore, following 
systemic administration, this molecule was detected in vivo 
by microdialysis in the neostriatum, reaching detectable 
(100  nM) concentrations in the dialysates116 and providing 
further evidence of its ability to cross the BBB.116 Moreover, 
repeated administration of salsolinol sensitized rats to the 
locomotor stimulant effects and led to significant increases 
in voluntary ethanol consumption, which was prevented by 
intra-posterior VTA pre-treatment with naltrexone.115
Finally, in this context, it is critical to mention that all 
the above-reviewed experimental evidence refers to salsoli-
nol (1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline) 
without any further specification, in particular, for its isomer 
(iso-salsolinol) and for its stereoselectivity. Indeed, in two 
well-designed studies, the group of Yedi Israel specified that 
these two critical caveats, related to the chemical nature of this 
molecule, should be clearly kept in mind in future research on 
this compound. The first caveat refers to the presence (roughly 
10–15%, w/w), in the commercially available salsolinol, of 
iso-salsolinol, a pharmacologically distinguishable isomer,115 
while the second refers to the fact that all the above-referenced 
evidence was originated with the use of the racemate, R,S-(±)-
salsolinol.116 As for the first issue, these authors reported that 
a number of effects, including drug-elicited CPP after either 
systemic administration or intra-posterior VTA of the com-
mercially available salsolinol, were indeed attributable to iso-
salsolinol  -free salsolinol. Quintanilla et al116 also elegantly 
demonstrated that the effects of racemate salsolinol could 
indeed be attributed only to (R)-salsolinol since the admin-
istration of (R)-salsolinol, but not of (S)-salsolinol, leads to 
CPP and locomotor sensitization and markedly increases vol-
untary ethanol consumption.116
Conclusions
The reviewed literature supports the tenet of a key role of acet-
aldehyde in the central behavioral and neurochemical effects 
of ethanol and robustly highlights the role of peripherally 
and centrally produced acetaldehyde in central effects at the 
basis of ethanol-mediated reinforcement. Furthermore, recent 
studies from independent groups brought to the demonstra-
tion that ethanol could act as the pro-drug of the condensation 
product between acetaldehyde and dopamine103 and that this 
condensation product, salsolinol, does indeed exert its actions 
as iso-salsolinol -free115 as well as (R)-salsolinol enantiomer.116 
Finally, although still in the absence of clear-cut demonstra-
tion of the binding affinity of this compound for μ opioid 
receptors, evidence has accumulated to suggest that this might 
indeed be the case.107,109,111–113 All this notwithstanding, some 
aspects of the pharmacological profile of acetaldehyde still 
remain unknown, mostly due to its poor detectability that 
would greatly help the understanding of the mechanism(s), 
the kinetic(s), as well as the site(s) of its peripheral and central 
actions; in contrast, iso-salsolinol -free (R)-salsolinol seems to 
be mainly involved in the central effects of ethanol in particu-
lar with respect to its actions mediated through the dopami-
nergic mesolimbic system.
Although much progress has been made in identifying 
pre-clinically the role of acetaldehyde and salsolinol in the 
central effects of ethanol, the translation of this knowledge 
into the clinical setting, including their role, following an 
acute, pharmacologically significant, ethanol exposure in the 
development of AUDs, is still far to be fully disclosed. More-
over, it is important to note that in addition to acetaldehyde 
and salsolinol, other metabolites may play a role. Notably, 
many of them are used in forensic medicine as markers of eth-
anol intake in drinkers.96,97 Finally, while it has not even been 
established whether ethanol-derived acetaldehyde is quantita-
tively transformed into salsolinol, it remains that acetaldehyde 
and salsolinol involve different systems and receptors impli-
cated in ethanol effects.
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In conclusion, it appears reasonable to suggest that inter-
fering with peripheral or central ethanol metabolism as well as 
decreasing acetaldehyde bioavailability could be the main tar-
gets of future discoveries of pharmacological tools able to reduce 
and/or prevent the development and the persistence of AUDs. 
More importantly, from now on, it should be kept in mind that 
both the brain and liver peroxidative statuses are involved in the 
control of the acute and chronic pharmacological effects of etha-
nol. Thus, changes in the physiological situations, that is, in the 
levels of H2O2 present in the liver and in the brain may represent 
a particular circumstance within the (same) organism respon-
sible to regulate some effects induced by ethanol. Furthermore, 
all data obtained with drugs able to reduce H2O2 (4-MP, 3-AT, 
and a-LA) and acetaldehyde production/availability could be 
particularly important to help understanding the mechanism(s) 
underlying the deepest roots of ethanol binge drinking and the 
relationship between ethanol and its metabolites.
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